19:26 , Dec 21, 2018 |  BC Week In Review  |  Clinical News

Achillion discontinuing PNH monotherapy

Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) said it will discontinue development of ACH-4471 as oral monotherapy treatment of paroxysmal nocturnal hemoglobinuria in favor of an earlier stage compound. The decision is a delay for Achillion as it...
19:21 , Dec 21, 2018 |  BC Week In Review  |  Clinical News

Roche, Chugai PNH candidate well tolerated in Phase I/II

Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) said SKY59 (RG6107; RO7112689) was well tolerated with no treatment-related serious adverse events reported in patients with paroxysmal nocturnal hemoglobinuria (PNH) who received the humanized mAb targeting complement 5 (C5)...
00:47 , Dec 19, 2018 |  BC Extra  |  Clinical News

Achillion down after discontinuing PNH monotherapy

Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) lost $0.45 (19%) to $1.95 on Tuesday after it said it will discontinue development of ACH-4471 as oral monotherapy treatment of paroxysmal nocturnal hemoglobinuria in favor of an earlier stage compound....
14:43 , Dec 11, 2018 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Myocardial infarction (MI) Cell culture and mouse studies identified a pyrimidinone-based inhibitor of TLR4 that could help treat MI. Chemical synthesis and screening of peptidomimetic analogs of a previously identified TLR4 inhibitor peptide in...
13:05 , Sep 14, 2018 |  BC Week In Review  |  Clinical News

Dicerna's DCR-PHXC reduces urinary oxalate levels in Phase I

Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) reported interim six-week data from the Phase I PHYOX trial showing that single subcutaneous doses of DCR-PHXC brought urinary oxalate levels into the normal or near-normal range in five of eight...
19:06 , Sep 7, 2018 |  BC Extra  |  Financial News

RNAi company Dicerna raises $100M follow-on

Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) gained $1.79 (14%) to $14.81 on Friday after raising $100 million via the sale of 7.7 million shares at $13.02 in a follow-on underwritten by Citigroup, Leerink, Stifel, H.C. Wainwright and...
02:02 , Jun 9, 2018 |  BioCentury  |  Product Development

POC for cytokines

A body of clinical evidence is emerging that two different approaches to immune-stimulating cytokine therapies could increase efficacy of PD-1 inhibitors in both hot and cold tumors. Oncologists who spoke to BioCentury said, taken together,...
19:51 , Apr 27, 2018 |  BC Week In Review  |  Clinical News

Alexion's long-acting C5 inhibitor meets in Phase III switch trial

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) reported in its 1Q18 earnings release on April 26 that ALXN1210, its long-acting formulation of Soliris eculizumab, met the primary and four key secondary endpoints in the the Phase III ALXN1210-PNH-302...
19:19 , Apr 26, 2018 |  BC Extra  |  Clinical News

Alexion gains on long-acting C5 inhibitor data, guidance

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) reported in its 1Q18 earnings release on Thursday that ALXN1210, its long-acting formulation of Soliris eculizumab, met the primary and four key secondary endpoints in the the Phase III ALXN1210-PNH-302 trial...
23:19 , Apr 20, 2018 |  Company News  |  Company News

Dicerna, Alnylam settle RNAi dispute

Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) gained $1.82 (18%) to $12.01 Friday after the company said it had resolved all litigation with Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) regarding RNAi-based treatments for primary hyperoxaluria, with neither company admitting wrongdoing....